Proven Track Record
Numbers that speak for themselves.
Accredited Investor Profiles
Years of Experience
Campaigns Supported
Capital Raise Supported
Trusted by Industry Leaders
“Growth Turbine and Varun Sharma have been instrumental in supporting Land Invest Corp's capital raise, bringing a highly strategic and data-driven approach to investor outreach. Their team consistently generates strong, qualified interest.”
Randy Goldberg
CEO, Land Invest Corp
“Growth Turbine is by far the best fundraising agency we've worked with. Their deep understanding of investor behavior and compliance-first approach makes them the go-to partner for any serious capital raise.”
Ryan Pierce
Wefunder
“Working with Growth Turbine has been a great experience. They've been highly engaged, incredibly responsive, and consistently willing to go the extra mile to support our Crowdfunding raise.”
David Kirschbaum
REtokens INC
“Huge fan of Growth Turbine and the work they are doing. Their expertise in investor acquisition is unmatched, and they consistently deliver results that move the needle for issuers on our platform.”
Jonny Price
VP, Wefunder
“Growth Turbine has been an excellent partner for our issuers. Their data-driven approach and compliance-first mentality sets them apart from every other agency in this space.”
Hunter Nicholas
Issuance
“We value our relationship with Growth Turbine and look forward to continuing to work together. Their investor acquisition capabilities and platform expertise have been a real asset to our ecosystem.”
Ryan Zega
tZERO
“Partnering with Growth Turbine has helped us drive growth across our issuer base. Their team brings real expertise and a results-oriented mindset to every engagement.”
Paul Matiychuk
Dealmaker
“Varun at Growth Turbine is legit. The depth of knowledge, the hands-on execution, and the genuine care for client outcomes — that's what sets them apart in this space.”
Justin Renfro
Director, Wefunder
Why BioTech Fundraising Is Different
Biotech investors underwrite milestones. If you cannot articulate the clinical path, indication strategy, IP position, and what each dollar achieves, your investor interest will not convert.
Scientific Validity & Differentiation
Mechanism, data quality, reproducibility, and what truly differentiates the approach.
IP Defensibility
Composition, method, and freedom‑to‑operate considerations that support a durable moat.
Indication Strategy & Competition
Choice of indications, sequencing, and positioning against current and emerging competitors.
Clinical & Regulatory Pathway
Trial phases, endpoints, timelines, regulatory strategy, and key risk points.
Capital Efficiency & Milestones
What each tranche of capital achieves in terms of data, endpoints, and inflection events.
Evidence‑Based Story & Use of Proceeds
Clear separation between what is proven vs hypothesis and capital tied to milestone‑based use of proceeds.
Featured Case Studies
Your BioTech Investor Demand Plan
Optimal Raise Structure
Reg CF vs Reg D 506(c) vs Reg A+ aligned with your stage and evidence.
Investor Audience Strategy
Accredited investors, biotech‑aligned operators, and strategic profiles where relevant.
Resonant Messaging
Messaging that translates complex science into investable clarity with milestone discipline.
Compliant Funnel & Outreach
A compliant funnel and qualification system that filters unserious prospects and investor nurture sequences that address IP, clinical path, and risk questions.
What's Included in Our BioTech Investor Acquisition System
A complete system for biotech investor acquisition.
Capital Strategy & Investor Positioning
- Align the raise structure to your stage and evidence.
- Position your raise around data quality, IP defensibility, and milestone-based capital deployment.
- Tailor messaging to biotech investor expectations around indication strategy and clinical pathway.
Compliant Funnel & Conversion Architecture
- Design funnels that qualify seriousness and educate investors.
- Diligence-ready funnels that educate investors on science before scheduling calls.
- Qualification flows that identify investors comfortable with pre-revenue biotech risk profiles.
Investor Traffic & Outreach
- Deploy targeted acquisition to reach accredited investors and biotech‑aligned profiles.
- Campaigns targeting investors experienced with biotech, life sciences, and clinical-stage companies.
- Creative built around pipeline visualization, data readouts, and regulatory milestone timelines.
Investor Nurture & Engagement
- Sequences that address common biotech questions—data, IP, indication, pathway, and risk.
- Education sequences covering preclinical data, IP portfolio, and competitive landscape.
- Objection handling for biotech concerns: clinical risk, development timeline, and dilution.
Reporting & Pipeline Intelligence
- Full visibility into lead quality, engagement, and conversion across the funnel.
- Pipeline analysis segmented by investor biotech experience and risk tolerance.
- Optimization focused on which data milestones and scientific proof points drive commitment.
Is BioTech Investor Acquisition Right for You?
We work best with BioTech teams that meet these criteria.
Strong Fit
- You have credible data or validation signals (preclinical, clinical, published, or partnered).
- You can clearly articulate milestones, endpoints, and timeline assumptions.
- Your IP strategy and differentiation are coherent and defensible.
- You want a structured, measurable investor acquisition process.
Not a Fit
- No traction and no credible plan to validate quickly.
- Overstated claims not supported by data.
- Looking for guaranteed fundraising outcomes.
- Unwilling to maintain disciplined disclosure and compliance.
Frequently Asked Questions
Biotech investors typically prioritize data quality, mechanism of action differentiation, IP defensibility, indication strategy, clinical pathway viability, and milestone-based capital efficiency. They evaluate whether the science is sound, whether the team can execute the development plan, and whether the capital deployment strategy is realistic given the clinical timeline ahead.
We build claims-safe positioning that clearly separates proven preclinical or clinical results from planned future research. All messaging is reviewed to ensure it accurately represents the current stage of development without making forward-looking efficacy claims. We focus on evidence quality, IP strength, and team credibility as the foundation of investor narratives.
Yes, many successful biotech raises are pre-revenue. The key is positioning around strong preclinical data, defensible IP, a clear clinical pathway, and milestone-based capital deployment. Investors in early-stage biotech understand pre-revenue risk but expect disciplined capital plans and rigorous evidence standards.
We use progressive qualification that educates investors on your science, competitive landscape, and development timeline before they reach your team. Each stage of the funnel provides deeper technical context that naturally filters casual interest from genuine biotech investors. This ensures your team spends time only with informed, aligned prospects.
Most biotech campaigns take 6–14 weeks to launch, depending on clinical complexity, regulatory sensitivity, and the depth of scientific content required. Pre-IND and clinical-stage companies may need additional time for investor education material development. We work to compress timelines while maintaining the scientific rigor investors expect.
Yes, many successful biotech raises are pre-revenue. The key is positioning around data quality, IP defensibility, clinical pathway, and milestone-based capital deployment. We help biotech teams build compelling investor narratives that clearly separate proven results from planned research and tie capital use to specific development milestones.
Which Regulation Is Right for Your Biotech Raise?
Framework selection depends on clinical stage, raise size, and investor sophistication.
| Feature | Reg CF | Reg D 506(c) | Reg A+ |
|---|---|---|---|
| Max Raise | $5M / 12 months | Unlimited | $75M / 12 months |
| Investor Type | Anyone (retail + accredited) | Accredited only | Anyone (retail + accredited) |
| Best For Biotech | Consumer-health biotech with community support | Clinical-stage companies targeting sophisticated investors | Late-stage biotech seeking broad public participation |
| Compliance Complexity | High (clinical claims sensitivity) | Moderate-High | Very High (SEC + clinical disclosures) |
| Timeline to Launch | 8–12 weeks | 8–14 weeks | 4–7 months |
Explore Related Industries
Discover more industries where we help founders attract investors and raise capital.
Health Tech, Pharma & Healthcare Investor Acquisition
Attract investors for healthtech and pharmaceutical innovations improving patient outcomes.
Learn moreAI & Machine Learning Investor Acquisition
Connect with investors backing AI-driven research and computational biology platforms.
Learn moreEnvironment & Sustainability Investor Acquisition
Reach impact investors interested in sustainable biotech and green chemistry innovations.
Learn more